Xtandi patents?

Xtandi (enzalutamide) is protected by a family of patents owned by Astellas and Medivation (now Pfizer). The patent family covers:

- Core composition-of-matter patent for enzalutamide (the chemical entity itself).
- Method-of-use patents covering treatment of prostate cancer and metastatic castration-resistant prostate cancer (and related indications).
- Additional patents around formulations, methods, and potential combination use (various jurisdictions).

Key points to know:
- The exact expiration dates depend on the country and any patent term extensions or pediatric extensions that may apply.
- In major markets, patent protection generally extends into the late 2020s or early 2030s, but the precise dates vary by jurisdiction.
- Generics are not broadly available in the US while these patents (and any extensions) are in force; timing of any entry depends on the specific patent expirations in each market and any legal challenges.

If you’d like, I can fetch current patent numbers and expiration dates for specific jurisdictions (e.g., US, EU, UK, Japan, Canada). Just tell me which country or region you care about.